| Basics |
Mersana Therapeutics, Inc.
Mersana Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.
|
| IPO Date: |
June 28, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$138.84M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.30 | 3.90%
|
| Avg Daily Range (30 D): |
$0.29 | 2.27%
|
| Avg Daily Range (90 D): |
$0.28 | 3.14%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.11M |
| Avg Daily Volume (30 D): |
.15M |
| Avg Daily Volume (90 D): |
.09M |
| Trade Size |
| Avg Trade Size (Sh.): |
170 |
| Avg Trade Size (Sh.) (30 D): |
62 |
| Avg Trade Size (Sh.) (90 D): |
71 |
| Institutional Trades |
| Total Inst.Trades: |
1,417 |
| Avg Inst. Trade: |
$1.69M |
| Avg Inst. Trade (30 D): |
$.81M |
| Avg Inst. Trade (90 D): |
$.81M |
| Avg Inst. Trade Volume: |
.24M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$2.6M |
| Avg Closing Trade (90 D): |
$2.6M |
| Avg Closing Volume: |
227.87K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.51
|
|
|
Diluted EPS
|
|
$-1.51
|
|
|
Revenue
|
$
|
$ 11.01M
|
$
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -7.55M
|
$ -24.3M
|
|
Operating Income / Loss
|
$
|
$ -7.67M
|
$
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jul 28, 2025:
1:25
|
|
|
|
